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Indications for allo- and auto-SCT for haematological
diseases, solid tumours and immune disorders: current practice
in Europe, 2015
A Sureda1, P Bader2, S Cesaro3, P Dreger4, RF Duarte1, C Dufour5, JHF Falkenburg6, D Farge-Bancel7, A Gennery8, N Kröger9, F Lanza10,
JC Marsh11, A Nagler12, C Peters13, A Velardi14, M Mohty15,17 and A Madrigal16,17 for the European Society for Blood and Marrow
Transplantation
This is the sixth special report that the European Society for Blood and Marrow Transplantation regularly publishes on the current
practice and indications for haematopoietic SCT for haematological diseases, solid tumours and immune disorders in Europe. Major
changes have occurred in the field of haematopoietic SCT over the last years. Cord blood units as well as haploidentical donors
have been increasingly used as stem cell sources for allo-SCT, thus, augmenting the possibility of finding a suitable donor for a
patient. Continuous refinement of conditioning strategies has also expanded not only the number of potential indications but also
has permitted consideration of older patients or those with co-morbidity for a transplant. There is accumulating evidence of the
role of haematopoietic SCT in non-haematological disorders such as autoimmune diseases. On the other hand, the advent of new
drugs and very effective targeted therapy has challenged the role of SCT in some instances or at least, modified its position in the
treatment armamentarium of a given patient. An updated report with revised tables and operating definitions is presented.
Bone Marrow Transplantation advance online publication, 23 March 2015; doi:10.1038/bmt.2015.6
INTRODUCTION
This report is the sixth report from the European Society for Blood
and Marrow Transplantation (EBMT) classifying allogeneic and
autologous haematopoietic SCT (HSCT) procedures according to
prevailing clinical practice in Europe.1–5 Since the first report,
major changes have occurred in clinical practice based on new
scientific and technical developments. This includes the recogni-
tion of new indications but also changed indications for HSCT
based on important developments in results of HSCT in non-
haematological malignancies, including autoimmune diseases,
and on novel non-transplant treatment strategies of haematolo-
gical and non-haematological malignancies. New strategies based
on cord blood stem cells (CB) or haploidentical donors have
significantly expanded the accessibility of allo-SCT (allo-HSCT)
approaches. Limitations for the transplant procedures such as age
and co-morbidities have been modified because of the introduc-
tion of reduced-intensity conditioning (RIC) regimens. The
updated proposed indications are presented in Tables 1 and 2.
As in the previous reports, we have attempted to summarize the
opinions and practice of clinicians working in transplant centres in
Europe in 2015. The EBMT recommendations are based on
existing prospective clinical trials, registry data and expert opinion,
but not on a formal extensive review of the literature. Therefore,
some recommendations have been made based upon analogy,
inference and expertise. Each section of the recommendations has
been discussed within the appropriate working party of the EBMT.
The EBMT recommendations are not meant to decide for an
individual patient whether a transplant is the correct choice of
procedure. It is also outside the scope of this report to classify
indications based on the use of a particular conditioning regimen
or a particular stem cell source. The classifications are aimed to
give guidance and have to be considered together with the risk of
the disease, the risk of the transplant procedure and the results of
non-transplant strategies. When the recommendations are inter-
preted, it is important, besides a possible survival gain, to assess
issues of quality of life and late effects into the risk assessment
strategy. Such effects are especially important in children and
adolescents.
DEFINITIONS
Haematopoietic stem cell transplant (HSCT)
HSCT refers to any procedure where haematopoietic stem cells of
any donor type and any source are given to a recipient with the
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Table 1. Proposed classification of transplant procedures for adults—2015








AML CR1 (low risk)a CO/II D/II GNR/II CO/I
CR1 (intermediate)a S/II CO/II D/II S/I
CR1 (high risk)a S/II S/II CO/II CO/I
CR2 S/II S/II CO/II CO/II
CR3, incipient relapse S/III CO/III D/III GNR/III
M3 Molecular persistence S/II CO/II GNR/III GNR/III
M3 Molecular CR2 S/II CO/II GNR/III S/II
Relapse or refractory CO/II CO/II D/II GNR/III
ALL Ph (− ), CR1 (standard risk)a D/II GNR/II GNR/III CO/III
Ph (− ), CR1 (high risk)a S/II S/II CO/II GNR/III
Ph (+), CR1 S/II S/II CO/II CO/III
CR2, incipient relapse S/II S/II CO/II GNR/II
Relapse or refractory CO/II D/II D/II GNR/III
CML 1st CP, failing TKI S/II S/II CO/III GNR/II
Accelerated phase or41st CP S/II S/II CO/II D/III
Blast crisis S/II S/II CO/II GNR/III
Myelofibrosis Primary or secondary with an
intermediate or high DIPSS score
S/II S/II S/III GNR/III
MDS RA, RCMD, RAEB I and II S/II S/II S/II GNR/III
sAML in CR1 or CR2 S/II S/II S/II CO/II
More advanced stages S/II S/II S/II GNR/III
CLL Poor risk disease S/II S/II D/III GNR/I
Lymphoid malignancies
DLBCL CR1 (intermediate/high IPI at dx) GNR/III GNR/III GNR/III CO/I
Chemosensitive relapse, ⩾CR2 CO/II CO/II D/III S/I
Chemosensitive relapse after auto-HSCT
failure
S/II S/II CO/III GNR/III
Refractory disease CO/II CO/II D/III CO/II
MCL CR1 D/III D/III GNR/III S/I
CR/PR41, prior auto-HSCT no CO/III CO/III D/III S/II
CR/PR41, prior auto-HSCT yes S/II S/II CO/III GNR/II
Refractory CO/II CO/II D/III GNR/II
FL CR1 GNR/III GNR/III GNR/III D/II
Chemosensitive relapse, ⩾CR2 CO/III CO/III GNR/III S/II
⩾CR2 after auto-HSCT failure S/II S/II D/III GNR/III
Refractory CO/II CO/II CO/III GNR/III
WM CR1 GNR/III GNR/III GNR/III D/II
Chemosensitive relapse, ⩾CR2 GNR/III GNR/III GNR/III CO/II
Poor risk disease CO/II CO/II D/III GNR/III
TCL CR1 CO/II CO/II GNR/III CO/II
Chemosensitive relapse, ⩾CR2 S/II S/II CO/III CO/II
Refractory CO/II CO/II CO/III GNR/II
Primary CTCL EORTC/ISCL Stages I–IIA (Early) GNR/III GNR/III GNR/III GNR/III
EORTC/ISCL Stages IIB–IV (Advanced) CO/III CO/III D/III GNR/III
HL CR1 GNR/III GNR/III GNR/III GNR/I
Chemosensitive relapse, no prior auto-
HSCT
D/III D/III GNR/III S/I
Chemosensitive relapse, prior auto-
HSCT
S/II S/II CO/III CO/III
Refractory D/II D/II D/III CO/III
MM CO/I CO/II GNR/III S/I
AL CO/III CO/III GNR/III CO/II
Other diseases
Acquired SAA Newly diagnosed S/II S (children)/II;
CO (adults) /II
GNR/III NA
Relapse/Refractory S/II S/II CO/II NA
Acquired AA/PNH Newly diagnosed S/II CO/II GNR/III NA
Relapse/Refractory S/II S/II CO/II NA
Haemolytic PNH GNR/II GNR/II GNR/II NA
Constitutional SAA Fanconi anaemia S/II S/II CO/II NA
Dyskeratosis congenital S/II S/II CO/II NA
Breast cancer Adjuvant high risk, HER2-negative GNR/III GNR/III GNR/III CO/II
Metastatic, chemosensitive D/II D/II GNR/III D/CO/II
Germ cell tumours Second line, high risk GNR/III GNR/III GNR/III CO/II
Primary refractory, second & further
relapse
GNR/III GNR/III GNR/III S/II
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intention of repopulating and replacing the haematopoietic
system in total or in part. Stem cells can be derived from BM,
PB or CB. The goal of the procedure should be defined beforehand
and a documented informed consent of the patient (and donor)
obtained before the procedure.
Donor categories
Donor type is categorized as autologous, syngeneic, HLA-identical
sibling donor, other family donor or unrelated donor. A well-
matched unrelated donor (MUD) is defined as a 10/10 or 8/8
identical donor based on HLA high-resolution typing for class I
(HLA-A, -B, -C) and II (HLA-DRB1, -DQB1). A mis-matched unrelated
donor (MMUD) refers to an adult unrelated donor mismatched in
at least one Ag or allele at HLA-A, -B, -C or –DR.6 There is growing
evidence that not all HLA mismatches are created equal.
Permissive HLA mismatches seem to confer similar transplant-
related outcomes when compared with matched donor sources,
presumably reflecting the inability of the T cell to recognize an
intrinsic HLA sequence difference.7 A non-permissive HLA allele
mismatch combination leads to a poorer outcome.8–10 MUD
transplants increase donor availability but take time to organize
because of donor screening and graft retrieval.
A haploidentical donor is defined as a family member where
only one HLA haplotype is genetically identical with the patient.
The advantages of transplantation from a haploidentical donor
include the availability for almost all patients, choice of best donor
from a panel of candidate family members, no undue delay in
obtaining the graft and easy access to donor-derived cellular
therapies if needed after the SCT procedure. Major drawbacks
used to be the very strong graft-vs-host and host-vs-graft
alloresponses11 with a high incidence of severe GVHD and graft
rejection after the HSCT. From the 1980s onwards, attempts
to overcome the HLA barrier focused on strengthening myeloa-
blation and immunosuppression in the conditioning regimen12,13
or on partially depleting the graft of T cells using anti-thymocyte
globulin or the T10B9 monoclonal Ab in conjunction with in vivo
immunotoxin14 and with post-transplantation CY and steroids. A
major advance came with strategies comprising myeloablative
conditioning based on TBI followed by transplantation of a mega-
dose of extensively T-cell-depleted mobilized PBSC. This ensured a
high engraftment rate in the absence of GVHD and has given
similarly good results in both children and adults with high-risk
acute leukaemia than MUD HSCT.15–19 In recent years, interest in
T-cell-replete full haplotype-mismatched HSCT was reawakened
by new strategies for GVHD prophylaxis. The use of high-dose
post-transplantation CY to prevent graft rejection and GVHD after
nonmyeloablative conditioning and T-cell-replete BM transplanta-
tion has been extensively pioneered by the Baltimore and Seattle
groups and has given promising results in terms of PFS and OS in
particular in patients with lymphoid malignancies with acceptable
rates of graft failure, GVHD and non-relapse mortality (NRM).20–22
International registries often lack complete information on HLA
typing reports of unrelated donor transplants. To understand the
impact of incomplete HLA characterization, the Center for
International Blood and Marrow Transplant Research (CIBMTR)23
analysed 14 797 unrelated donor HSCT (1995–2006) using multi-
variable regression modelling adjusting for factors affecting
survival and identified three groups with significantly different
outcomes; well-matched cases had either no identified HLA
mismatch and informative data at 4 loci or allele matching at
HLA-A, -B and -DRB1, partially matched pairs had a defined,
single-locus mismatch and/or missing HLA data, and mismatched
cases had ⩾ 2 allele or Ag mismatches. Multivariate 5-year survival
estimates were significantly different for the previously estab-
lished groups of patients and the authors suggested that these
Table 1. (Continued )







Ovarian cancer High risk/recurrent D/II GNR/III GNR/III GNR/I-II
Medulloblastoma Post-surgery, high risk GNR/III GNR/III GNR/III D/CO/III
Small cell lung cancer Limited GNR/III GNR/III GNR/III D/I-II
Soft tissue sarcoma Metastatic D/III GNR/III GNR/III GNR/II




D/III GNR/III GNR/III CO/III
Renal cell carcinoma Metastatic, cytokine-refractory D/II D/II GNR/III GNR/III
Pancreatic cancer Advanced D/III GNR/III GNR/III GNR/III
Colorectal cancer Metastatic D/III GNR/III GNR/III GNR/III
Multiple sclerosis D/III GNR/III CO/II
Systemic scleroderma D/III GNR/III CO/II
Systemic lupus erythematosus D/III GNR/III CO/II
Crohn’s disease GNR/III GNR/III CO/II
Rheumatoid arthritits GNR/III GNR/III CO/II
Vasculitis GNR/III GNR/III CO/II
Polymyositis-dermatomyositis GNR/III GNR/III CO/II
CIPD GNR/III GNR/III CO/II
NMO GNR/III GNR/III CO/II
Cytopenias CO/II CO/II CO/II
T1D GNR/III GNR/III D/III
RCD type II GNR/III GNR/III D/III
Abbreviations: AA= aplastic anaemia; AL= amyloidosis; CLL, chronic lymphocytic; CO= clinical option, can be carried after careful assessment of risks and
benefits; CP= chronic phase; CR1, 2, 3= first, second, third CR; CTCL= cutaneous T-cell lymphoma; D=developmental, further trials are needed;
DIPSS=Dynamic international prognostic score system; DLBCL=diffuse large B cell lymphoma; FL= follicular lymphoma; GNR=generally not recommended;
HL=Hodgkin lymphoma; IPI= International prognostic index; M3= Promyelocytic leukaemia; MCL=mantle cell lymphoma; MM=multiple myeloma;
PNH=paroxismal nocturnal haemoglobinuria; PR, partial remission; RA= refractory anaemia; RAEB= refractory anaemia with excess blasts; RCMD= refractory
cytopenia with multilineage dysplasia; S= standard of care generally indicated in suitable patients; SAA= severe aplastic anaemia; sAML= secondary AML;
TCL= T-cell lymphoma; TKI= tyrosine kinase inhibitors; WM=Waldenstrom macroglobulinaemia. This classification does not cover patients for whom a
syngeneic donor is available. Alternative donors denote MMUD, Cord Blood, Haploidentical Transplants. Well-matched unrelated donor= 10/10, 8/8, 9/10 (if
mismatch in DQB1). aCategories are based mainly on number of WBCs, cytogenetics at diagnosis and molecular markers, and time to achieve remission
according to international trials.247
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proposed HLA sub-groupings could be used when complete HLA
typing was not available. Furthermore, this improved categoriza-
tion of HLA matching status could standardize interpretations of
prior unrelated donor HSCT experience. This classification should
only be used for retrospective analysis purposes but not to
prospectively classify the degree of mismatching between a given
donor and patient.
Stem cell sources
There are three commonly used sources of haematopoietic stem
cells: BM, cytokine-mobilized PB progenitor cells (PBSC), and
CB cells.
For autologous HSCT (auto-HSCT), PBSC is the preferred choice
because of a more rapid haematopoietic reconstitution. In cases of
insufficient mobilization with G-CSF-based regimens, in many
patients, an adequate harvest can be achieved with the use of
inhibitors of the interaction between CX chemokine receptor 4
(CXCR4) and stromal derived factor-1 alpha (SDF-1), such as
plerixafor.24–26 For allo-HSCT, all three stem cell sources are used
and have their specific advantages and disadvantages. PBSCs are
associated with more rapid engraftment but are associated also
with an increased risk of chronic GVHD compared with BM.27 The
higher risk for chronic GVHD might therefore make PB HSCT a less
attractive option for children, or for some patients with early stage
disease. In some countries, it is prohibited to give G-CSF to donors
who are o18 years old. Furthermore, the additional graft-vs-
malignancy effect seen in patients with chronic GVHD is not
applicable for patients with non-malignant conditions such as
severe aplastic anaemia (SAA). BM is therefore seen as the
preferred choice in SAA when using ATG-based conditioning
regimens.28,29 The donor’s preferences must also be taken into
account as there are differences in the side effects experienced by
the donors from a BM or PBSC harvest.
Table 2. Proposed classification of transplant procedures for children—2015
Disease Disease status Sibling donor allo-HSCT Well-matched URD allo-HSCT/CBT Alternative donor allo-HSCT ASCT
Haematological malignancies
AML CR1 (low riska) GNR/II GNR/II GNR/III GNR/II
CR1 (high riska) S/II CO/II CO/III CO/II
CR1 (very high riska) S/II S/II CO/II CO/III
CR2 S/II S/II S/II CO/II
4CR2 S/II CO/II CO/II GNR/II
ALL CR1 (low riska) GNR/II GNR/II GNR/III GNR/II
CR1 (high riska) S/II S/II CO/II GNR/II
CR2 S/II S/II CO/II GNR/II
4CR2 S/II S/II CO/II GNR/II
CML Chronic Phase CO/II CO/II CO/II GNR/III
Advanced Phase CO/II CO/II CO/II GNR/III
NHL CR1 (low risk) GNR/II GNR/II GNR/II GNR/II
CR1 (high risk) CO/II CO/II CO/II CO/II
CR2 S/II S/II CO/II CO/II
HL CR1 GNR/II GNR/II GNR/II GNR/II
1st relapse, CD2 CO/II CO/III CO/III S/II
MDS S/II S/II CO/III GNR/III
Disease Sibling donor allo-HSCT Well-matched URD allo-HSCT /CBT Alternative donor allo-HSCT ASCT
Non-malignant disorders; solid tumours
Primary immunodeficiencies S/II S/II S/II NA
Thalassemia S/II CO/II CO/III NA
Sickle cell disease (high risk) S/II CO/III CO/III NA
Aplastic anaemia S/II S/II CO/II NA
Fanconi anaemia S/II S/II CO/II NA
Blackfan-Diamond anaemia S/II S/II CO/III NA
Chronic granulomatous disease S/II S/II CO/III NA
Kostman’s disease S/II S/II CO/III NA
MPS-1H Hurler S/II S/II CO/II NA
MPS-1H Hurler Scheie (severe) GNR/III GNR/III GNR/III NA
MPS-VI Maroteaux-Lamy CO/II CO/II CO/II NA
Osteopetrosis S/II S/II S/II NA
Other storage diseases GNR/III GNR/III GNR/III NA
Autoimmune diseases CO/II CO/II GNR/II CO/II
Germ cell tumour CO/II CO/II CO/II CO/II
Ewing’s sarcoma (high risk or 4CR1) D/II D/III D/III S/II
Soft tissue sarcoma (high risk or 4CR1) D/II D/II D/III CO/II
Neuroblastoma (high risk) CO/II D/III D/III S/II
Neuroblastoma 4CR1 CO/II D/III D/III S/II
Wilm’s tumour 4CR1 GNR/III GNR/III GNR/III CO/II
Osteogenic sarcoma GNR/III GNR/III GNR/III D/II
Brain tumours GNR/III GNR/III GNR/III CO/II
Abbreviations: CBT= cord blood transplant; CO= clinical option, can be carried after careful assessment of risks and benefits; CR1, 2= First, second CR;
D=Developmental, further trials are needed; GNR=Generally not recommended; HL=Hodgkin lymphoma, generally indicated in suitable patients;
MDS=Myelodisplastic syndrome; MPS=Mucopolysaccaridosis; NHL=Non Hodgkin lymphoma. Well-Matched Unrelated Donor= 10/10, 8/8. 9/10 (if mismatch
in DQB1). This classification does not cover patients for whom a syngeneic donor is available. aCategories are based mainly on number of WBCs, cytogenetics
at diagnosis and molecular markers, and time to achieve remission according to international trials.
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Unrelated CB cells are commonly used when patients lack an
HLA-identical sibling or a MUD. An additional advantage is that CB
cells can be obtained rapidly and may therefore be a better option
when a patient needs an urgent HSCT. The indications for the use
of CB as a source for stem cells in children are identical to the
indications listed in Table 2 for MUD transplants. CB units should
be selected by HLA matching and cell dose. The most important
factor influencing outcome is the cell dose and a minimum dose
of 2.5–3 × 107 nucleated cells/kg body weight of recipient at
collection or 2 × 107 nucleated cells/kg at infusion is recom-
mended; a higher dose of 44 × 107 nucleated cells/kg is needed
for SAA patients. HLA disparity should not exceed two of six
defined by HLA-A, -B Ag and HLA-DRB1 allele typing. According to
registry analyses, outcomes of unrelated CB HSCT in children and
adults with acute leukaemia are comparable with MUD BM
transplants.30,31 In adults with relapsed/refractory lymphoproli-
ferative disorders, unrelated CB HSCT achieves comparable
outcomes than those of RIC unrelated HSCT.32
To overcome the cell-dose limitation, Barker et al.33 pioneered
the use of double cord blood transplant, sequentially infusing 2 CB
units instead of 1. The results were encouraging, with all patients
engrafting neutrophils in a median of 23 days (range, 15–41). The
requirements of cell dose and number of HLA disparities for the
double units are the same as for single units. Thus, no more than
two of six HLA disparities should exist between each CB unit and
the patient. Interestingly, the incidence of acute GVHD seems to be
higher after double cord blood transplant although this fact does
not impact on NRM34 and the relapse rate is lower35 in comparison
with a single unit cord blood transplant. A registry analysis
suggested that in patients with acute leukaemia being allografted
with a myeloablative conditioning regimen, double cord blood
transplant seems to be a associated to a lower relapse rate in
comparison with matched related donors, MUD and 1-Ag MMUD
although NRM is higher, thus rendering no significant differences in
terms of leukaemia-free survival (LFS), supporting the use of two
partially HLA-matched CB units when patients lack an HLA-matched
donor.36 Several single centre and retrospective analysis support
the use of RIC regimens in the setting of cord blood transplant.37–40
Combined transplantation of a single CB unit with CD34+ stem
cells from a HLA-mismatched auxiliary donor (haplo-cord) reliably
reduces the time to neutrophil engraftment, in comparison with
other CB strategies, to approximately day +12.41–43 In addition,
haplo-cord provides comparable overall outcomes to other donor
sources while allowing the use of single CB units with relatively
low cell content, and expands donor availability reducing CB cell
dose requirements.
Nowadays, and with a patient being a potential candidate for an
allo-HSCT who lacks a HLA well-matched donor (HLA identical
sibling/MUD), physicians are faced with the need to select
amongst different options: MMUD, CB or haploidentical trans-
plants. Despite the large number of phase II and observational
studies, the dearth of randomized trials makes the prioritization of
an alternative donor difficult and the decision may in part reflect
the research agenda of the transplantation centre because no one
source of stem cells is clearly superior to another. If a donor is
urgently required, CB and haploidentical transplantation have the
advantage over adult volunteer MMUD. If upfront costs are a
concern, haploidentical family members have a clear advantage
over CB and MMUD. For patients with prior infectious problems,
CB may be the less desirable stem cell source because of the
delayed haematopoietic recovery and immune reconstitution.
Finally, not all mismatches in the MMUD setting are equal.
Reduced intensity conditioning (RIC) regimens
The hypothesis that graft-vs-tumour effects are capable of eradicat-
ing malignant disorders led to the development of RIC regimens
that made allo-HSCT an accessible therapeutic option for older and
medically infirm patients who previously were not considered
candidates for high-dose conditioning. Not even nowadays, has full
consensus on how to define a RIC regimen been achieved by the
HSCT community. The EBMT definition considers that any regimen
with 50% or less equivalence to a standard conditioning regimen is
considered reduced intensity. This includes not only the 50%
reduction of the total dose of a given drug (or TBI), but also the use
of a single drug in a standard dose but without other drugs (or TBI)
usually included in the standard protocol (http://www.ebmt.org/
Contents/Data-Management/Registrystructure/MEDABdatacollec
tionforms/Documents/MED-ABFormsManual.pdf). RIC regimens are
being increasingly used in the last years and represent more than
70% of all transplantation procedures in some disease categories.
Most of these regimens have been evaluated in phase 1 or 2 trials
only, but there is a paucity of randomized phase 3 trials in the field.
Retrospective registry-based studies comparing myeloablative
conditioning protocols with RIC regimens44–46 indicate that the
latter are associated with a lower NRM but with a higher relapse
rate after the procedure thus, not significantly modifying long-
term outcome of these patients both in terms of PFS and OS. In
children with AML, NRM, relapse rate, PFS and OS were not
significantly different between myeloablative protocols and RIC
regimens.47 In refractory/relapsed Hodgkin lymphoma (HL),
children and adolescents had a better PFS because of a higher
relapse rate after a RIC-allo that was not accompanied by a higher
NRM in the myeloablative setting.48 A randomized prospective
clinical trial performed in young patients with AML in first
remission49 indicates that RIC regimens result in a similar
incidence of NRM and reduced toxic effects compared with
standard conditioning without affecting survival outcomes, and
thus could be preferentially used in this setting. The role of
reduced intensity is yet to be defined in the younger population of
patients and additional prospective clinical trials are needed.
RISK FACTORS FOR OUTCOME
The initial analysis performed by Gratwohl50 indicated that the
main risk factors for outcome after HSCT were the stage of the
disease, the age of the patient, the time interval from diagnosis to
transplant and, for allo-HSCT, the donor/recipient histocompat-
ibility and the donor/recipient sex combination (EBMT score). NRM
increases and survival rates decrease with advanced disease stage,
increasing age, increasing time from diagnosis to transplant,
increase in HLA disparities, and for male recipients having a
female donor. All components should be integrated into the risk
assessment and the decision making for a transplant. In the case
of transplant for non-malignant diseases, such as for autoimmune
disorders, NRM and PFS were shown to vary according to original
diseases, centre activity and conditioning.51–53 More recently
and with the development of non-myeloablative regimens and
improvements in the supportive care after myeloablative proto-
cols, more patients with co-morbidities are being offered allo-
HSCT. Investigators from the Fred Hutchinson Cancer Research
Center in Seattle developed the HSCT-specific co-morbidity index
(HCT—CI) that integrates chronic medical conditions, which are
important in predicting NRM in HSCT patients, thus producing a
new scoring system that also assesses survival probabilities after
allo-HSCT.54 Further refinement of this HCT-CI indicates that
Karnofsky status at transplantation is an independent prognostic
factor,55 that HCT-CI is predictive of survival across different
haematological malignancies56–58 and that, as expected, age is a
poor prognostic factor with a bigger negative impact in those
patients with higher HCT-CI.59 Patients without co-morbidities
usually tolerate non-myeloablative and myeloablative condition-
ing regimens equally well, whereas those with co-morbidities
(whether young or old) have better survival after RIC protocols.
The calculation of the transplantation-associated risk in a given
patient is of capital importance nowadays taking into
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consideration the fair competition existing between a potentially
curative but more toxic treatment approach (for example, HSCT)
and a non-curative but less toxic and better-tolerated strategy (for
example, targeted therapy).
THE IMPACT OF A QUALITY SYSTEM ON THE OUTCOME OF
HSCT
JACIE (Joint Accreditation Committee of ISCT Europe and EBMT)
was started in Europe at the end of the 1990s. JACIE pursues
improving the outcome of HSCT by doing it within a standardized
and approved quality management system. There is increasing
evidence that adherence to standardized quality management
policies within an accredited program improves the outcome of
allo-HSCT.60,61
CATEGORIZATION OF TRANSPLANT PROCEDURES
An important aim of the EBMT indication documents has been to
classify indications and to give advice about the settings where
these types of transplants ought to be performed. These have
been classified as ‘standard of care’, ‘clinical option’, ‘develop-
mental’ or ‘generally not recommended’.
Standard of care (S)
Indications categorised as ‘standard of care’ are reasonably well
defined and results compare favourably (or are superior) to those
of non-transplant treatment approaches. Obviously, defining an
indication as the standard of care does not mean an HSCT is
necessarily the optimal therapy for a given patient in all clinical
circumstances. ‘Standard of care’ transplants may be performed in
a specialist centre with experience with HSCT procedures and an
appropriate infrastructure as defined by the JACIE guidelines.
Clinical option (CO)
The Clinical Option (CO) category is based on the fact that, for
many indications, the number of patients will be low and
therefore randomized studies comparing conventional treatment
and HSCT are difficult to perform. Results of small patient cohorts
treated for this disease by HSCT show efficacy and acceptable
toxicities of the procedure. The broad range of available transplant
techniques combined with the variation of patient factors such as
age and co-morbidity makes interpretation of these data difficult.
Our current interpretation of existing data for indications placed in
this category supports HSCT as a valuable option for individual
patients after careful discussions of risks and benefits with the
patient but the value of HSCT needs further evaluation for groups
of patients. Transplants for indications under this heading should
be performed in a specialist centre with major experience with
HSCT procedures, with an appropriate infrastructure as defined by
JACIE guidelines.
Developmental (D)
Indications have been classified as developmental if there is
limited experience with this indication in combination with the
type of transplant and when additional research is needed to
define the role of HSCT. These transplants should be done within
the framework of a clinical protocol. Such a protocol can either be
a randomized comparison of two or more approaches to
treatment or a small pilot series undertaken by transplant units
with acknowledged expertise in the management of that
particular disease or that type of HSCT. The category also covers
fundamentally new approaches to the management of a disease
that, in a different stage, may already be classified under the
standard of care or clinical option. Protocols for ‘developmental’
transplants will have been approved by local research ethics
committees and must comply with current international stan-
dards. Rare indications where formal clinical trials are not possible
should be performed within the framework of a structured registry
analysis, ideally an EBMT non-interventional/observational study. It
is implied that the results of the study are intended for
presentation to and/or publication for the medical community
at large. Centres performing transplants under the category of
‘developmental’ should meet JACIE standards. The document for
Rules and Regulations for EBMT Clinical Trials could also be used
as a guideline (http://www.ebmt.org/1WhatisEBMT/Op_Manual/
OPMAN16_Clinical%20Trials%20Guidelines.pdf).
Generally not recommended (GNR)
The GNR category can include early disease stages when results of
conventional treatment do not normally justify the additional risk
of NRM, or when the disease is so advanced that the chance of
success is so small that the risk of the harvest procedure for the
normal donor is difficult to justify. GNR may not apply to specific
situations where a syngeneic donor exists. This category also
includes HSCT for a disease in a phase or status in which patients
are conventionally not treated by HSCT. Therefore, there will be
some overlap between GNR and D, and further research might be
warranted within prospective clinical studies for some of these
indications. GNR does not exclude that centres with a focus on a
certain disease can investigate HSCT in these situations.
Data reporting
Reporting of transplant data is mandatory for EBMT members and
the minimum amount of data to be reported is contained in the
MED-A form. To fully assess the impact of certain transplant
strategies for specific indications, reporting of data on a larger
case record form (MED-B data) is encouraged.
Evidence grading
There has been no attempt to perform a formal evidence review
as the basis for the indication classification but a broad
classification has been made as described below. In this
classification, results from other therapeutic strategies than HSCT
have also been taken into account.
1. Evidence from at least one well-executed randomized trial
2. Evidence from at least one well-designed clinical trial without
randomization; cohort or case-controlled analytic studies
(preferably from more than one centre); multiple time-series
studies; or dramatic results from uncontrolled experiments
3. Evidence from opinions of respected authorities based on
clinical experience, descriptive studies or reports from expert
committees.
STATUS OF TRANSPLANTS IN SPECIFIC DISEASES IN ADULTS
The updated classification of HSCT procedures in adults is shown
in Table 1.
Acute myeloid leukaemia (AML)
Adult patients with AML should always be considered for a HSCT,
either allo-HSCT or auto-HSCT. Progress has been made with the
two modalities in the recent years so that previous guidelines
necessitate updating. Patients with good prognosis AML by
cytogenetics/molecular markers such as patients with core
binding factor leukaemia (t(8;21), inv(16) or t(16;16)), patients
with mono- and even biallelic gene mutation in the CCAAT/
enhancer binding protein α gene (CEBPA), and patients with
mutation in NPM1 but no FlT3ITTD for whom any transplant in first
CR (CR1) was previously not recommended should now be
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evaluated for consolidation with an auto-HSCT in CR1 if in
molecular remission with no marker detectable in the leukapher-
esis products; or for an allogeneic transplant with an HLA identical
sibling but not with an alternative donor. These recommendations
come from numerous reports, including studies of the EBMT,62
and the meta-analysis of several randomized studies63 on 2983
patients analysed for CEBPA mutational status, which showed that
relapse-free survival was significantly superior in patients receiving
an allo-HSCT or an auto-HSCT in CR1 as compared with
chemotherapy (Po0.001), with a trend for a better OS
(Po0.12). As confirmation is still needed, auto- and allo-HSCT
with a genoidentical donor in these patients is at present a CO,
awaiting classification as standard of care.
Patients in CR1 but clinically slow responders (needing more
than one course of induction to achieve CR1, or as a surrogate
marker an interval from diagnosis greater than 40 days), and/or
with other poor prognosis indicators such as M5 or M6 by FAB
classification, poor cytogenetics defined as a complex karyotype
(more than three abnormalities) or monosomy 7, inv(3)(q21q26),
t(6;11)(q27;q23), t(6;9)(p23;q34) or t(11;19)(q23;p13.1)64 and/or
those with the FLT3ITD or MLL molecular mutation, should be
allografted with the best available donor including genoidentical
family members, unrelated donors, CB and haploidentical donors,
as part of a standard of care approach; auto-HSCT is not
recommended.
All other patients in CR1 with other cytogenetic abnormalities or
normal karyotype belonging to the intermediate risk category are
candidates for all kinds of HSCT from a well HLA-matched related
or unrelated donor. Auto-HSCT has recently regained interest,
thanks to several improvements such as reduced NRM with the
introduction of IV BU in the pre-transplant regimen,65 better
monitoring of MRD by immunophenotyping66 and molecular
biology such as WT1 overexpression67 and, possibly, with
the introduction of maintenance therapy post autologous
transplantation.68 Analyses of other molecular markers as indica-
tors of AML subsets with distinct prognosis are increasingly being
used for decision purposes, but are still under validation.69,70 At
the present time, some therapeutic trials evaluate risk-adapted
and MRD-directed transplant strategies where MRD-negative
patients are autografted and MRD-positive patients allografted.
In these patients, allo-HSCT is standard of care and auto-HSCT
remains a clinical option waiting for further assessment. However,
although there are considerable data showing better outcome of
allo-HSCT with genoidentical donors over auto-HSCT, there are no
such data when comparing auto-HSCT to allogeneic transplanta-
tion with alternative donors. In addition to that, the quality of life
is better after an autologous than an allogeneic transplant.71
Therefore, in MRD-negative patients, auto-HSCT is a clinical option
while waiting for results of randomized studies, to possibly reach
an upgrade in the categorization of transplant procedure. A recent
retrospective study from CIBMTR72 has concluded that in the
absence of a matched sibling donor, auto-HSCT may provide an
acceptable alternative post-remission therapy for patients with
AML in CR1.
Patients with AML 3 achieving CR2 and MRD negativity should
be autografted (S), because the outcome is similar or better than
after allogeneic transplantation.73–75
Acute lymphoid leukaemia (ALL)
The field of HSCT in adult ALL remains controversial. The
introduction of more aggressive chemotherapy regimens from
the models developed in children to adolescents and young
adults has reduced the need for allogeneic transplantation in most
patients younger than 35 years of age. In contrast, allo-HSCT
remains the standard of care in high-risk patients such as slow
remitters or steroid and/or chemotherapy-resistant patients,
patients over 35 years of age and all patients following relapse
post CR1. Regarding standard risk patients, a recent randomized
study comparing the outcome of 433 adult ALL patients,
according to a sibling donor vs no-donor comparison has resulted
in a LFS at 5 years significantly better in the donor group: 60 vs
42% (hazard ratio: 0.60; P= 0.01).76,77
In a large EBMT retrospective study performed in 200378 on a
total of 1402 patients allografted from 1990 to 2000 with a
genoidentical donor, it was possible to identify three prognostic
groups based on three prognostic factors: age (below and over
35 years), response to induction (rapid and slow remitters) and
donor sex. Group 1 (good prognosis) included patients aged o35
years old, achieving CR1 with one induction course and to be
transplanted with any other sex combination than female to male
(score 0), group 2 (intermediate) with one adverse factor (score 1)
and group 3 (bad prognosis) with two or three adverse criteria
(scores 2 and 3). The 3-year LFS was 56%, 48% and 29% and the
OS was 65%, 53% and 29%, respectively. Some recent studies have
readdressed the question of auto-HSCT: for instance, a meta-
analysis using data from 13 studies including 2962 patients,79
excluding Philadelphia chromosome-positive (Ph pos) patients,
showed a survival benefit for those patients having a matched
sibling donor and for patients younger than 35 years of age
(OR= 0.79, P= 0.0003) but not for older ones (OR = 1.01, P= 0.9)
because of the higher absolute risk of NRM for older patients. No
beneficial effect of autografting was seen compared with
chemotherapy in this analysis.
In this context, the place of autologous transplant is difficult to
assess. In patients over the age of 55, a very recent retrospective
EBMT study (Giebel S, personal communication) on 267 patients
treated with a RIC-allo and 179 patients autografted in CR1,
showed better results for auto-HSCT, with a probability of OS at
2 years of 44% for RIC-allo and 57% for auto-HSCT (P= 0.02), owing
to a significantly reduced NRM for auto-HSCT (23% vs 11%,
respectively, P= 0.002).
In Ph pos patients, a recent EBMT retrospective study80
indicates that results of auto-HSCT have significantly improved
over time: the probability of OS at 3 years increased from 16% for
transplants performed between 1996 and 2001 to 48% between
2002 and 2006 and 57% between 2007 and 2010 (Po0.0001);
LFS was 11%, 39% and 52%, respectively (Po0.0001). Relapse
incidence decreased from 70 to 45% and 45% (P= 0.01),
respectively, while NRM was 19%, 15% and 3% (P= 0.08). In a
multivariate analysis, year of auto-HSCT was the only independent
factor influencing the risk of treatment failure (hazard ratio = 0.37;
Po0.001). In a subgroup of 22 patients treated with tyrosine
kinase inhibitors (TKI) and being in complete molecular remission
at the time of the autologous transplant, the LFS rate at 3 years
was 65%. Data have been accumulated over time indicating that
auto-HSCT at the time of MRD negativity obtained with the
contribution of TKI is associated with good outcomes.
Adults with ALL with persistent or relapsing MRD are candidates
for allo-HSCT in CR1 from either an HLA-identical sibling or an
unrelated donor. Allo-HSCT for standard risk patients in CR1
should be performed whenever possible within a clinical protocol.
Patients relapsing after chemotherapy and achieving CR2 are
candidates for allo-HSCT from an HLA-identical sibling, an
unrelated donor or other alternative donors such as CB or
haploidentical donor. For patients with either Ph pos or Ph
negative (Ph neg) ALL with negative MRD status, auto-HSCT is a
clinical option. The role of maintenance therapy post autologous
transplant remains unknown despite old favourable reports.81
Chronic myeloid leukaemia (CML)
HSCT remains the only curative treatment for CML. However, after
the advent of TKI, allo-HSCT cannot be recommended to all
patients with a suitable donor as first-line treatment after
diagnosis. Imatinib should be the first-line therapy for all patients
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in chronic phase. Some patients in molecular remission after
treatment with imatinib have remained in molecular remission for
a median of 24 months after cessation of the drug.82 Patients with
suboptimal response or failure to first-line therapy according to
the European Leukaemia Net (ELN) guidelines should start a
search for a suitable donor as early as possible (sibling or
unrelated). They should receive treatment with second line TKI
and are candidates to proceed to HSCT in optimal response as
soon as possible if their EBMT risk score is 0–1 or in case of a prior
loss of cytogenetic or haematological response to imatinib if their
EBMT risk score is 0–4. If there is no haematological response to
second line treatment, patients are candidates for allo-HSCT on
any EBMT risk score (these patients may benefit from treatment
with third line TKI prior to HSCT depending on ABL mutation
analysis). Patients with ABL mutations known to be resistant to
second generation TKI are candidates to undergo HSCT if their
EBMT risk score is 0–4 after failing imatinib.
Patients in advanced phase referred for a HSCT could have
therapy with TKI or intensive therapy ± TKI as preparation for
HSCT. HSCT should be performed as soon as possible after
achieving second chronic phase without the need to achieve deep
cytogenetic or molecular responses. Patients in second chronic
phase are candidates for allo-HSCT from an HLA-identical sibling,
an unrelated donor, or other alternative donors such as CB or
haploidentical family donor. A patient with a syngeneic donor is
always a candidate for a HSCT with standard conditioning.
Auto-HSCT should only be recommended in the context of clinical
studies.
Myeloproliferative disorders other than CML
Allo-HSCT is today the only curative option for patients with
myeloproliferative disorders. Polycythaemia vera and essential
thrombocythaemia are, in general, not indications for allo-HSCT
unless the disease has progressed to myelofibrosis or secondary
leukaemia.83
Owing to the lack of alternative therapeutic options, allo-HSCT
is a reasonable treatment for primary myelofibrosis with
intermediate II and high risk according to the Dynamic Interna-
tional Prognostic Index (DIPSS). Myelofibrosis post-essential
thrombocythaemia or -polycythaemia vera and should also be
considered an indication for allo-HSCT for all patients younger
than 65 years of age.84 In younger patients, transplantation in
intermediate I is justified in individual cases. The experience of
allo-HSCT with low-risk DIPSS is limited and remains controversial.
The available data do not support splenectomy prior to HSCT. The
introduction of JAK inhibitors in the treatment of myelofibrosis
may help to improve constitutional symptoms and to reduce
spleen size before transplantation. Auto-HSCT is not recom-
mended and should be performed only in a clinical trial.
Myelodysplastic syndromes (MDS)
Allo-HSCT is considered the treatment of choice for adult patients
with MDS or AML evolved from MDS and offers a good chance of
long-term disease-free survival, if the treatment is performed
before progression of the disease or if the patient is transplanted
in CR after chemotherapy. The International Prognostic Score
System (IPSS) is a valuable tool to assess a patient’s prognosis
without HSCT. Additional prognostic factors, such as multilineage
dysplasia and transfusion requirement, may be considered as
well.85 The results seem to be better in allo-HSCT if the blast count
does not exceed 5% at the time of transplant. The practice in
Europe is to treat MDS patients with excess of marrow blasts with
remission-induction therapy, but this approach has not been
substantiated by prospective clinical trials. Treatment with
azacytidine before HSCT is another option to reduce the risk for
relapse, but has not yet been proven. The decision to proceed
with allo-HSCT should be based on the risk of the disease and the
risk of the transplant procedure as estimated by the EBMT risk
score. The results of a large European study show that auto-HSCT
can be recommended in patients with good-risk cytogenetic
characteristics.86
Chronic lymphocytic leukaemia (CLL)
Allo-HSCT from an HLA-identical sibling or MUD is a treatment
option for young patients having previously been treated with
and progressing after fludarabine-containing regimens and have
poor-risk disease as defined by clinical and cytogenetic/molecular
assessments.87 Mature phase-II studies and registry analyses have
shown that allo-HSCT is the only therapy with curative potential. In
contrast to conventional treatment, it can provide long-term
disease control even in genetically unfavourable and refractory
cases, and is clearly superior to any other salvage chemotherapy.88
The promising new class of BTK, PI3K and BCL2 inhibitors may be
considered as treatment alternative in patients who are at high
risk of treatment-related mortality.
Lymphomas
Diffuse large B-cell lymphoma (DLBCL). Auto-HSCT remains the
standard of care for patients with chemosensitive relapse of
DLBCL in the rituximab era.89–91 With regard to the value of auto-
HSCT as consolidation after rituximab-containing first-line therapy
of DLBCL, a survival benefit for HSCT could not be shown in
several randomized phase-III trials.91,92 Therefore, upfront auto-
logous HSCT cannot be considered as treatment standard in
DLBCL. Auto-HSCT is less effective in patients with chemorefrac-
tory DLBCL but can result in long-term survival in a significant
minority of them.93
Patients who relapse after auto-HSCT for DLBCL have only
limited effective treatment perspectives. Although the available
evidence is largely based on registry studies, it appears that allo-
HSCT can provide long-term disease control in up to 40% of
patients with DLBCL who have failed auto-HSCT, in particular if
performed in chemosensitive disease.94,95 Accordingly, allo-HSCT
should be considered as a rescue option in eligible patients with
this condition.91 This notion is supported by a phase-II prospective
study.96 The value of allogeneic in comparison with auto-HSCT in
high-risk relapse or refractory status of DLBCL needs to be defined
by further studies.
Follicular lymphoma (FL). Although in the rituximab era still not
proven by a prospective randomized trial, auto-HSCT is considered
as standard treatment option in patients who are in first or
subsequent relapse of FL.91,97 In contrast, prospective phase-III
trials from the pre-rituximab as well as from the rituximab era have
failed to show a survival benefit of consolidating auto-HSCT
performed in first FL remission,98 implying that upfront auto-HSCT
in FL should be performed only within the framework of a
prospective clinical trial.91,97 Results of auto-HSCT in truly
refractory FL are poor. These patients should be offered alternative
approaches. Long-term follow-up of retrospective studies of auto-
HSCT for relapsed FL concordantly show that disease recurrence
becomes increasingly infrequent after 6–8 years of follow-up,
indicating that auto-HSCT could have curative potential in a
subset of patients with FL.99 Disease control after auto-HSCT might
be further improved by rituximab maintenance as shown in a
randomized phase-III clinical trial.100
FL generally appears to be highly sensitive to graft-vs-
lymphoma effects, translating into a pronounced efficacy of allo-
HSCT in terms of relapse prevention in this disease.101,102
However, owing to the good efficacy of first-line immuno-
chemotherapy and in the absence of valid predictors of adverse
outcome, there is no place for allo-HSCT in FL in first remission.
Similarly, investigators tend to prefer immunochemotherapy
with or without auto-HSCT for second-line treatment of FL.
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A prospective trial randomizing autologous vs allo-HSCT in this
condition had to be closed prematurely because of slow
accrual.103 Supported by evidence from several retrospective
uncontrolled studies, allo-HSCT therefore is reserved as a
potentially curative option for those patients who have failed
auto-HSCT or multiple therapy lines, or who have become
refractory.91,97,104
Waldenström’s macroglobulinaemia (lymphoplasmacytic lymphoma
with IgM gammopathy) (WM). Small retrospective studies and a
large registry analysis suggested that auto-HSCT might improve
the outcome of WM when applied as first-line consolidation.105,106
With the event of more effective agents, such as rituximab, purine
analogues and bortezomib, this approach is increasingly ques-
tionable and should not be followed outside of clinical trials. In
contrast, auto-HSCT is an option for salvage therapy in selected
patients with chemosensitive disease who have not been exposed
to numerous treatment lines.106,107 There is circumstantial
evidence (effects of DLI and chronic GVHD, plateau in the relapse
curves, efficacy in refractory disease) from registry studies that
graft-vs-lymphoma is effective in WM.108,109 Thus, allo-HSCT has
been advocated as a treatment option for younger individuals
with aggressive clinical course.110 Although a clear definition of
high-risk WM is missing, indications for allo-HSCT might be
considered along the criteria for poor-risk CLL (purine analogue
refractoriness and relapsed disease with TP53 lesion).87
Mantle cell lymphoma (MCL). Auto-HSCT consolidation is
considered as standard part of first-line treatment of younger
(o60–65 years) patients with MCL.93 This is based on several
uncontrolled studies and one prospective randomized trial
comparing auto-HSCT consolidation with IFN maintenance in
patients with MCL in first remission.111 This trial demonstrated that
auto-HSCT provides a significant PFS benefit, and—after longer
follow-up—also an OS benefit over IFN.112 The results of upfront
auto-HSCT in MCL can be further improved by incorporation
of rituximab and high-dose ara-C into the induction regimen
as observed in prospective randomized trials and cohort
studies.113,114 A registry analysis suggested that the benefit of
auto-HSCT may also be relevant in fit elderly patients (65–70
years).115 The prognosis of patients with relapsed or refractory
MCL relapse is generally poor. Although the results of salvage
auto-HSCT are inferior to first-line transplants, auto-HSCT remains
a rescue option for transplant-naïve patients.93,116,117
Although merely supported by retrospective studies, in the
absence of reasonable alternative treatment options, allo-HSCT
seems to be the only modality capable of providing long-term
disease control in patients with relapsed and even refractory
MCL.117,118 Therefore, it is consensus to recommend allo-HSCT to
patients with MCL who relapse or become refractory after auto-
HSCT or an appropriately intensive pre-treatment.93 In contrast,
there is no evidence to support upfront allo-HSCT in MCL outside
of clinical trials. It remains to be shown whether novel molecular
drugs, such as B cell receptor kinase inhibitors, will affect HSCT
indications in MCL or other B cell malignancies in the future.119
T-cell lymphomas. Peripheral T-cell lymphomas usually carry a
very poor prognosis. On the basis of results from phase II trials and
registry analyses, auto-HSCT as consolidation of a first response
represents a reasonable treatment option,120–122 whereas its role
in the relapse setting is less clear. It might be best supported in
chemosensitive ALCL-type peripheral T-cell lymphomas without
prior autologous transplantation.123 The value of allo-HSCT as first-
line consolidation in peripheral T-cell lymphoma is still under
investigation. In contrast, phase II trials and registry analyses
strongly support the notion that allo-HSCT is effective in relapsed
and refractory peripheral T-cell lymphoma and the only curative
modality in this condition.122–126
Mycosis fungoides (MF) and Sézary syndrome are the most
common forms of primary cutaneous T-cell lymphomas.127
Although early stage MF has an excellent outcome, patients with
EORTC/ISCL stages IIB to IV MF and Sézary syndrome have a
dismal prognosis with conventional therapy, with median survivals
of only 1–3 years from the time of diagnosis.128–130 Auto-HSCT can
induce cutaneous T-cell lymphoma responses in these patients,
but they are almost universally very short-lived, with median time
to progression of 2–3 months, and therefore it is generally not
recommended as a therapeutic strategy.131 Conversely, allo-HSCT
offers patients with advanced-stage MF and Sézary syndrome a
clinically relevant and persistent graft-vs-MF/Sézary syndrome
effect, leading to OS rates of 54% at 3 years, 46% at 5 years and
44% at 7 years,132,133 which despite the lack of well-designed
comparative trials, would suggest this to be an advantageous and
potentially curative option for these patients compared with their
outcomes with only conventional therapy.
Hodgkin lymphoma (HL). Auto-HSCT is the standard therapy for
patients with HL in first chemosensitive relapse or refractory to
first-line therapy but sensitive to salvage therapy as shown by two
prospective clinical trials.134,135 In contrast, there is no evidence
supporting auto-HSCT in first CR. For truly primary refractory
patients, for patients in chemo-refractory relapse, and for those
who relapse after a previous auto-HSCT, a second one has a
limited likelihood to induce durable remission, but it may be an
option in patients ineligible for allo-HSCT.136,137
Prospective phase II trials as well as retrospective cohort
comparisons and registry analyses suggest that allo-HSCT can
prolong survival in comparison with the limited non-transplant
options in patients who fail autologous HSCT but respond to
salvage therapy.136,138,139 Accordingly, allo-HSCT can be consid-
ered as the standard treatment option in eligible patients with
sensitive relapse after auto-HSCT.140 The value of allo-HSCT is less
established in refractory HL, but may be considered in the absence
of effective treatment alternatives.141
Multiple myeloma (MM)
Auto-HSCT is clearly indicated for patients less than 70 years of
age who respond to first-line treatment. Age should be considered
in conjunction with the patient’s general health and fitness. New
agents, such as the proteasome inhibitors (bortezomib) or the
immunomodulatory drugs such as lenalidomide (IMiDs) may
change the place of auto-HSCT. Ongoing studies are comparing
induction with a combination of new agents, such as proteasome
inhibitor with IMiDs, followed by upfront auto-HSCT vs delayed
transplantation. Therefore, the role of first-line auto-HSCT may be
challenged in the future. Best results are seen in patients
achieving good responses prior to HSCT but some non-
responding patients also benefit from this approach. High activity
shown by IMiDs and bortezomib before transplantation has
recently led to their use as consolidation and maintenance
therapies after auto-HSCT. Maintenance therapy with lenalidomide
post auto-HSCT may be considered. Two studies demonstrated an
improvement in PFS142,143 but an increase in OS in only one
study.143 Double auto-HSCT has been shown to be superior to one
auto-HSCT although the benefit of the second transplant appears
to be restricted to patients not achieving CR or very good PR with
the first transplant; consolidation and maintenance with agents
such as thalidomide may be an alternative for these patients.
However, the vast majority of patients still relapse. The use of a
further transplant after re-induction therapy is an option and may
be of particular benefit in patients achieving a long treatment-free
interval after their first transplant(s) (at least 18–24 months).144
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TBI should not be used in the conditioning regimen because of
increased toxicity without appreciable benefit.
Allo-HSCT is a treatment with curative potential, but is
associated with considerable NRM and might be used in selected
high-risk patients. The results of the combination of auto-HSCT
followed by RIC-allo are inconsistent. Two studies with long-term
follow-up of patients treated upfront reported a superior outcome
compared with single or double auto-HSCT.145,146 and a third
study shows a trend for better outcome.147 However, three other
studies with shorter follow-up have so far not shown any benefit.
Longer follow-up is needed. Some phase II studies of relapsed
patients show encouraging results and one that retrospectively
compared HSCT and RIC-allo based on the availability of a
matched donor showed better PFS with RIC-allo, however, with no
difference at 2 years in OS.148 The combination of auto-HSCT and
unrelated RIC-allo is currently being investigated. Similarly to the
autologous transplantation setting, new agents are complemen-
tary, non-redundant therapies and should be combined in the
management of suitable allogeneic patients.
AL amyloidosis
Patients with systemic immunoglobulin-light-chain (AL) amyloi-
dosis have been treated by auto-HSCT since 1994. A study with
matched controls showed that amyloidosis patients without
severe heart failure benefited from high dose therapy and auto-
HSCT. This was not confirmed in a randomized trial including
patients with advanced cardiac amyloidosis.149 Many recently
published studies reported an improved early mortality and
consistently good haematologic responses.
Allo-HSCT might be considered as a clinical option in younger
patients who relapsed or did not respond after HSCT and received
at least one new drug (lenalidomide or bortezomib).
Acquired severe aplastic anaemia (SAA)
First-line allogeneic HLA identical sibling HSCT is considered for
young and adult patients with SAA who have a matched sibling
donor.150–152 EBMT data show that outcomes of patients aged
30–40 years and 40–50 years are the same. However, a careful
assessment of co-morbidities prior to HSCT should be made to
determine fitness for up-front HSCT in the age group of 35–50
years, instead of first-line immunosuppressive therapy (IST) with
ATG (preferably with horse ATG) and CYA; it is also advised to seek
further advice from an AA specialist centre.
Patients transplanted from matched sibling donors and
agedo30 years should receive conditioning with high dose CY
(200mg/kg), and for patients aged 30–50 years a fludarabine-
based regimen with lower dose CY (120 mg/kg) used.153 All
patients should also receive in vivo T-cell depletion with ATG, or
alemtuzumab if available, because this will decrease the likelihood
of developing chronic GVHD. There is no indication for using
radiation in the conditioning for HLA identical sibling HSCT.
Allogeneic unrelated HSCT using a well-matched donor is
indicated after failure to respond to one course of IST.
A fludarabine-based regimen is recommended.154 Assessment
of response to IST is usually made at 3–6 months. BM is the
recommended stem cell source for HSCT in SAA from sibling
or unrelated donor HSCT for ATG-based conditioning
regimens.28,153,155,156 Studies are ongoing to determine whether
there is any preferred stem cell source for alemtuzumab-based
conditioning.
Alternative donor HSCT, using either CB cells157,158 or a
haploidentical family donor159,160 or a mismatch 9/10 donor,
may be considered in the absence of a matched sibling or
unrelated donor after failure to respond to IST. All patients should
be screened for donor-directed HLA antibodies as their presence
would preclude using that donor because of a predicted high risk
of graft rejection. For cord blood transplant, a minimum of 4 × 107/
kg total nucleated cells (frozen) is recommended. The current
EBMT AAWP approved protocol for either CB or haploidentical
HSCT should be followed.
Paroxysmal nocturnal haemoglobinuria (PNH)
The indications for HSCT in PNH have changed since the
introduction of C5 blocking monoclonal Ab therapy with
eculizumab. The current indications for HSCT depend on the
individual clinical manifestations of PNH, and are (i) AA/PNH
syndrome, that is, PNH occurring in the presence of severe BM
failure with a hypocellular BM (using the same factors of age,
disease severity, and for UD HSCT failure to respond to one course
of IST) and (ii) clonal evolution of PNH to MDS/AML.152,161,162
Severe recurrent thrombosis is no longer a mandatory indication
for HSCT, but can be taken into consideration when discussing the
patient’s treatment strategy and it may also be an option in
patients who have poor haematological response to eculizumab
(that is, remaining severely transfusion-dependent regardless of
anti-complement treatment). HSCT is not indicated for recurrent
haemolytic crises, except for patients in countries that cannot
afford eculizumab treatment. If needed, expert advice should be
sought from a PNH specialist centre. The timing of HSCT and
conditioning regimen in AA/PNH is the same as for acquired SAA
outlined above.
Constitutional SAA
There is increasing awareness that constitutional SAA, including
Fanconi anaemia and dyskeratosis congenita (DC) may not only
present in childhood but also in adults, often with more subtle
clinical features of the syndrome.
Allo-HSCT is the only treatment able to restore normal
haemopoiesis in patients with Fanconi anaemia. Patients who
have a suitably matched donor and who are transfusion-
dependent should be transplanted at a young age, as outcomes
are best before the age of 10 years. For matched siblings, excellent
survival has been obtained with low dose CY alone (60 mg/kg).163
In a recent very large EBMT study, the optimal conditioning
regimen was an irradiation-free, fludarabine-based conditioning
regimen.164 Standard doses of chemotherapy and/or irradiation
should be absolutely avoided in Fanconi anaemia HSCT, because
of the underlying defect in DNA repair. BM stem cells should be
used in preference to PBSC, as the latter is an independent risk
factor for later second malignancy. In the absence of a matched
sibling donor, a suitably matched UD should be considered, also
using a fludarabine-based regimen, but the addition of low-dose
irradiation may be indicated (and also for those patients with
clonal evolution) because of a higher risk of graft rejection.
For DC, most of published data concerning HSCT relate to
X-linked DC and indicate high mortality from liver and respiratory
failure, as a consequence of the more recently recognized clinical
features of DC, namely pulmonary fibrosis and cirrhosis. There are
only anecdotal reports of HSCT for autosomal dominant DC
because of TERC or TERT mutations in association with SAA. The
state of organ damage (lung, gastrointestinal, liver) is an important
factor for the eligibility of the patient for HSCT. For all types of SAA
associated with DC, a RIC regimen incorporating fludarabine is
currently recommended.165,166 Discussion with a specialist in BMF
is advised regarding possible HSCT.
Solid tumours
Auto-HSCT. Supported by a strong rationale from laboratory
studies and apparently ‘convincing’ results of early phase II
studies, in the nineties, high-dose chemotherapy with auto-HSCT
was uncritically adopted as a potentially curative option for solid
tumours. For this reason, randomized trials comparing high-dose
therapy with conventional control arm were difficult to conduct.
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As a result, the number and size of clinical studies initiated (and
often abandoned before completion) to prove or disprove its
value was largely insufficient. In fact, after a quarter of century of
clinical research and thousands of patients receiving high-dose
therapy, the benefit of a greater escalation of dose of
chemotherapy with auto-HSCT in solid tumours, with the possible
exception of selected patients with breast cancer (BC) and germ
cell tumours, is still unsettled.
Breast cancer (BC)
The role of auto-HSCT for primary BC at high risk of recurrence (at
least four involved axillary lymph nodes) has been assessed by
several randomized trials,167 recently evaluated by a meta-analysis
of individual patient data.168 Overall, it was shown that high-dose
therapy prolonged disease-free survival when used as adjuvant
therapy, and showed a benefit on BC-specific survival and OS in
selected cohorts of patients.169,170 Whether auto-HSCT has benefit
in the context of contemporary taxane-based regimens and
targeted therapies is largely unknown. Seven phase III studies
have been published in peer-reviewed journals.167,171 Most of
these trials showed improved PFS in the high-dose therapy arm,
but only one an OS advantage. Six randomized trials, including
866 metastatic BC patients, have been analysed in the parallel
meta-analysis of individual patient data,168 showing a significant
improvement in PFS but no improvement in OS.
Overall, based on the randomized studies so far, meta-analyses
and retrospective studies,172 auto-HSCT may still represent a
therapeutic option for well-informed younger patients harbouring
HER2-negative tumours and having gross involvement of axillary
nodes (adjuvant setting) or highly chemosensitive disease
(advanced setting).
Germ cell tumours
High-dose therapy is not recommended as first-line therapy in this
setting.173 In relapsed germ cell tumour, high-dose therapy
is considered to be a therapeutic option,174,175 especially when
poor prognostic factors are present.176 A randomized study
comparing conventional dose therapy with high-dose therapy is
planned. Auto-HSCT is a standard of care for patients who are
(primary) refractory to platinum-based chemotherapy or for those
with a second or further relapse, excluding primary mediastinal
disease.173 Multiple intensified cycles with carboplatin/etoposide
is recommended as the standard high-dose treatment for germ
cell tumour also owing to concerns that using a three-drug
regimen would require dose reductions of the two most active
drugs in this disease.
Other solid tumours
Data from randomized phase III studies comparing high-dose
vs conventional-dose chemotherapy for first-line treatment of
advanced ovarian cancer and limited or extensive small cell lung
cancer177,178 have shown no statistically significant difference
in PFS or OS. Limitations due to study design, difficulty in
recruitment and toxicity may have accounted for the lack of
favourable results, that were expected based on previous phase II
and retrospective analyses179 of such highly chemosensitive
diseases.
In other chemosensitive histologies, including sarcomas and
central nervous system tumours, data regarding autologous
transplantation in adult patients are limited, again based on
clinical trials without randomization and retrospective analyses.179
For this reason, high-dose therapy cannot be recommended as
standard of care and should be considered within prospective
studies when available. High-dose therapy can be regarded as a
potential clinical option in selected patients with Ewing’s sarcoma
180,181 and medulloblastoma.182
Allogeneic setting. There is no clinical experience of allografting
in renal cell cancer that is TKI- and mTOR-refractory; nowadays,
allo-HSCT should be considered, in renal cell cancer183 and other
solid tumours.184,185 only in the context of prospective studies.
Attempts to improve the therapeutic index of allo-HSCT in solid
tumours by innovative clinical strategies are underway.186
Cell therapy. Despite the great potential, cell therapy programs
for cancer control still have a marginal role in the management of
patients with solid tumours, although its use in the setting of
melanoma and other malignancies187–189 seems ready for
development as a routine therapy. This is due to limitations
inherent to the technologies and products employed, and to the
financial and structural burdens that are associated with cell
therapy.190 This issue should be regarded as a priority for medical
oncology and cell therapy/transplantation societies.
The story of SCT in solid tumours demonstrates the importance
of adopting an internationally co-ordinated approach to the
investigation of this treatment modality. There needs to be an
increased emphasis on prospective trials that are statistically
robust and have well-defined criteria for patient selection. Only
these will be able to demonstrate whether HSCT, alone or
incorporated into programs with novel therapeutic modalities, is
worthwhile in patients for whom conventional treatments have
often limited impact on survival.
Autoimmune diseases (AD)
Auto-HSCT should be considered for patients with severe AD
progressing despite standard established and/or approved therapy.
It has shown long-term prolonged survival with various degrees of
evidence according to each AD-specific conditions. Patients should
be referred to a centre with JACIE accreditation or equivalent,
where appropriate inter-disciplinary interaction with combined
haematological and AD specialists allow selection and manage-
ment of AD patients. Local or central biobanking, within regulatory
requirements, is essential to provide adequate serum, plasma and
cell samples in addition to biological samples according to each AD
category and organ involvement at baseline, during the
immunosuppression-free remission, and at potential relapse.
Adult patients with the underlying AD should be considered as
indications for auto-HSCT, when presenting: a) severe systemic
sclerosis and disease duration (i) of less than 5 years since onset of
first non-Raynaud’s symptoms and a modified Rodnan skin score
⩾ 15 plus respiratory (with a diffusing capacity of the lung for
carbon monoxide and/or forced vital capacity ⩽ 80% of predicted
and evidence of interstitial lung disease on high resolution
computed tomography scan), cardiac (with conduction or rhythm
disturbance, pericarditis) or renal involvement or (ii) of less than 2
years and no major organ dysfunction as defined above provided
they had a modified Rodnan skin score of at least 20 and an acute
phase response (level I);191 b) multiple sclerosis in the relapsing-
remitting phase, showing high clinical and MRI inflammatory
activity, with rapid deterioration despite the use of one or more
lines of approved treatments; the ‘malignant’ (Marburg) forms and
the secondary progressive disease, only when some inflammatory
activity is still evident, with clinical relapses and/or new T2 MRI
lesions on two subsequent scans, and with a sustained and
increased in disability in the previous year and with an EDSS upper
limit of 6.5, except for the malignant form (level II);192,193 c)
systemic lupus erythematosus early in the disease course, with
sustained or relapsed activity defined by a BILAG A category, with
either kidney (with a creatinine clearance 430ml/min/m2 on
renal biopsy of less than 12 months showing evidence of WHO
class III or IV glomerulonephritis), neurologic, cardiovascular or
pulmonary, vasculitis or autoimmune cytopenias after at least
6 months of the best standard therapy, using mycofenolate
mofetil or CY with or without anti-CD20 (level II);53 d) Crohn’s
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disease, refractory to immunosuppressive agents and anti-TNF
monoclonal antibodies, with sustained endoscopic or CT scan-
proven activity or extensive disease in which surgical resection
would expose the patient to the risk of small bowel syndrome or
with refractory colonic disease and perianal lesions where
coloprotectomy with a definitive stoma not accepted by the
patient (level II); e) autoimmune cytopenias with either immune
thrombocytopenia, autoimmune haemolytic anaemia and Evans’
syndrome refractory to at least two lines of treatment (including
rituximab and TPO-receptor agonists for immune thrombocyto-
penia) (level II); f) for other AD, including rheumatoid arthritis,
systemic vasculitis, dermatomyositis and polymyositis can be
considered as exceptional indications. Chronic demyelinating
inflammatory polyneuropathy and neuromyelitis optica, type 1
diabetes mellitus, refractory type II coeliac disease, autism
spectrum disorders potentially respond, but experience of auto-
HSCT has been relatively recent and patients should only be
treated on approved prospective clinical trials.
Syngeneic as an alternative to auto-HSCT may be considered
with comparable risks and potential greater benefit according to
donor-related issues. Allo-HSCT outside of a clinical trial is
highly discouraged in all ADs except for patients with immune
thrombocytopenia, autoimmune haemolytic anaemia and
Evans’ syndrome refractory to at least two lines of treatment
(including rituximab and TPO-receptor agonists for immune
thrombocytopenia) under the CO criterion.52
Both for adult and paediatric indications, specific recom-
mendations include patient selection, stem cell collection, graft
manipulation, conditioning regimens and supportive care.
Comprehensive cardiopulmonary screening and pre-transplant
evaluation are critically important to exclude patients at high risk
of NRM.194
Priming chemotherapy is recommended to enhance mobiliza-
tion whilst maintaining disease control and to prevent potential
flare, which may be a consequence of G-CSF alone (level I). The
recommended mobilization regimen is CY at 2–4 g/m2 with
uromixetan and cautious hyper hydration followed by G-CSF
5–10mcg/kg (level II). A minimum dose of 2 × 106/kg CD34+ cells
should be reinfused, irrespective of any graft manipulation
(level II). Among the many conditioning regimens reported, the
ADWP recommends CY 200mg/kg with polyclonal or monoclonal
anti-T-cell serotherapy generally, with CY 120 mg/kg, fludarabine
150mg/kg and anti-T-cell serotherapy as an alternative in
paediatrics and BEAM+anti-T-cell serotherapy in multiple sclerosis
specifically. After HSCT, all patients should remain under the direct
routine combined care of the transplant and the AD specialists for
at least the first 100 days post transplant, and then on a quarterly
basis for the first 2 years even if clinically stable. Thereafter, joint
annual review as a minimum is recommended. Long-term annual
data reporting, including late effects, of all AD patients after HSCT
to registries is a minimum recommendation.52
STATUS OF TRANSPLANTS IN SPECIFIC DISEASES IN CHILDREN
AND ADOLESCENTS
More than 20% of allo-HSCT are performed in patients below
20 years. However, at least one-third of HSCTs in children are
performed for rare indications. Clinical trials to improve outcomes
after HSCT in children have been limited by small numbers and
disease-specific complications. Distinct side and late effects are
exclusively related to the vulnerability of the developing organism,
including child-specific organ dysfunction, delayed hormonal
development, growth retardation, dental and skeletal damage,
and the high risk of malignancies in congenital disorders with
chromosomal breakage syndromes. During the last years, better
HLA matching with non-sibling donors, the evolution of RIC
regimen, better supportive care and better diagnosis of infectious
complications, dramatically reduced NRM. That enabled offering
allo-HSCT at an earlier disease course with better performance
status and not as ‘last chance for cure’. However, the burden of
acute and especially chronic GVHD is still a major limitation for
patients who do not identify well-matched donors and have to be
considered for outweighing the risk of this procedure. In such
situations, nowadays HSCT from haploidentical family donors or
from an unrelated CB might be performed within clinical studies in
highly experienced and specialized centres.
Acute myeloid leukaemia (AML)
Childhood AML is a rare and heterogeneous disease, cure rates
with intensive chemotherapy and extensive supportive care are
around 60%. Better outcomes are reported for patients with
favourable prognostic markers.195 Hence, HSCT is not recom-
mended as a front-line therapy for good-risk patients with
AML.196,197 Allo-HSCT from an HLA-identical sibling in CR1 remains
an option for children defined as high risk as it was proven to be
more efficient than chemotherapy in some comparative studies,
with EFS ranging from 55 to 72%.198,199 Infant AML and children
with FAB M0, M6 or M7 AML, who stand very poor chances of cure
by chemotherapy or by auto-HSCT, are indications for HSCT in first
remission.200 Results in children with AML undergoing haploiden-
tical HSCT have shown some effect of NK alloreactivity suggesting
that haploidentical HSCT may have a role in early phase very high-
risk AML patients.201,202
Auto-HSCT has been used as consolidation in children with
AML, in CR1 after induction therapy and represented a possible
alternative for high-risk children lacking a matched donor.
Nevertheless, results of paediatric studies comparing auto-HSCT
to chemotherapy were conflicting and are currently not recom-
mended outside prospective trials addressing new questions.203
Children who experience AML relapse and who reach second
remission are candidates for any kind of allo-HSCT. To improve
remission quality, and to reduce post-transplant relapse, several
studies are on the way, exploring new immunological mechanisms
and pharmaceutical developments.
Acute lymphoid leukaemia (ALL)
The indications for HSCT in children with ALL in CR1 are limited to
the subpopulation of high-risk ALL. Most study groups define
these patients as having estimated EFS of less than 50%. The risk
factors indicating the usefulness of HSCT are known molecular
biological markers or chromosomal abnormalities, and biological
factors including poor prednisone response, and resistance to
initial chemotherapy including persistence of MRD.204 MRD
became the most important prognostic factor for ALL relapse in
children and should be used for better discrimination of high-risk
and very high-risk groups.205,206 For the latter patients, allo-HSCT
from matched sibling donors or a well-matched unrelated donor
and for the highest risk category also a mismatched donor is an
option. Also, infants with very high-risk features benefit from allo-
HSCT and are candidates for both related and well-matched
unrelated HSCT.207 ALL patients, who experience an early or very
early marrow relapse, still have a dismal prognosis when treated
with conventional chemotherapy.208 Although nearly 90% achieve
a second remission, most of them subsequently develop
progressive disease. Both matched sibling donor HSCT and well-
matched unrelated donor HSCT are clearly indicated in these
patients since the outcomes are similar.209,210 If a matched sibling
or a well-matched unrelated donor cannot be identified, other
types of donors such as CB, mismatched unrelated donors or
haploidentical family donors can be indicated.19,211 In contrast to
adults, PBSC from HLA-compatible sibling donors show no
advantage for engraftment, relapse incidence and OS compared
with BM and therefore BM is the preferred stem cell source for
children.212
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Non-Hodgkin lymphoma
Nearly all children and adolescents are cured with multidrug
chemotherapy. Only few patients are eligible for allo-HSCT:
patients with residual disease after re-induction therapy of
contemporary chemotherapy-protocols or patients with early
NHL relapses and patients with inadequate response or relapse
of anaplastic lymphoma kinase-positive anaplastic large cell
lymphoma.213–215 All other approaches should be discussed with
the experts of the front line chemotherapy trials.
Chronic myeloid leukaemia (CML)
Although allo-HSCT is the only curative option for patients with
CML, the introduction of specific TKI has substantially modified the
treatment strategies for all age groups. As children and
adolescents have to be treated for an indefinite time with TKI, it
has become clear that toxicities may make long-term TKI therapy
less attractive compared with allo-HSCT.216,217 HSCT has long-term
complications of growth failure, infertility, chronic GVHD,
metabolic syndrome and secondary malignancies, whereas
prolonged TKI may cause growth failure, hepatic and cardiac
complications.216–218 Nowadays, it is accepted that all children and
adolescents with CML-CP should initially be treated with imatinib
and maintained with TKI therapy indefinitely if there is a good
response.219,220 No long-term results are evaluable to show
whether children will stay in sustained complete molecular
remission after TKI discontinuation. Further, it is considered that
allo-HSCT with an HLA-identical sibling donor or closely matched
unrelated donor is a clinical option for patients with treatment
failure or recurrence after receiving salvage second-generation TKI
treatment.221 Further, it is considered that allo-HSCT with an HLA-
identical sibling donor or closely matched unrelated donor can be
considered for patients with treatment failure or recurrence after
receiving salvage second-generation TKI treatment. However,
prospective cooperative studies are needed to address this
complex issue in young patients with CML.220,222
MDS, juvenile myelomonocytic leukaemia
Allo-HSCT from a sibling donor or a well-matched unrelated donor
is the treatment of choice for children with primary MDS including
juvenile myelomonocytic leukaemia, as well as secondary
AML.223–225 The role of auto-HSCT in children with MDS remains
controversial and is generally not recommended.
Inherited diseases
Primary immunodeficiencies. Primary immunodeficiencies are
genetic disorders characterized by defective or impaired innate
or adaptive immunity. Of these, severe combined immunodefi-
ciencies are the most severe, leading to death in infancy or early
childhood unless treated appropriately. Many other immunodefi-
ciencies lead to decreased quality of life with premature death
through childhood or early adulthood. Recurrent, persistent or
opportunistic infections are the classic hallmarks of primary
immunodeficiencies, although immunodysregulation or malig-
nancies are increasingly recognized presentations. Allo-HSCT can
cure most cellular immunodeficiencies affecting innate or
adaptive immunity. Advances in a number of areas including
earlier diagnosis, more accurate HLA-typing, an increasing range
of stem cell sources, less toxic conditioning regimens and
improved supportive care have enabled increasing successful
outcomes, of over 90% survival in some conditions. Owing to the
clinical heterogeneity of the patients, the several existing variants
for each primary immunodeficiency associated with the need to
carefully evaluate the patient’s clinical conditions, and the fact
that drugs are used in different dosages, combinations and time
schedules according to the disease, the age and the clinical
condition of the patient.
HSCT for primary immunodeficiency should be performed in a
centre regularly performing such transplants and actively
participating within EBMT’s inborn errors working party. The
guidelines for each particular inherited condition are published on
the EBMT’s website and reviewed regularly by the Inborn Errors
working party members.226 Allo-HSCT is indicated for severe
primary immunodeficiencies from both HLA-identical and alter-
native donors, including umbilical CB.
Severe combined immunodeficiency. The diagnosis of SCID is a
paediatric emergency, and these patients should undergo HSCT as
soon as possible. An allo-HSCT results in a survival rate of more
than 90% when carried out shortly after birth.227 Factors
that influence prognosis include the age, the type of SCID
(B lymphocyte+ vs B lymphocyte− ), and the clinical state at the
time of diagnosis, in particular the presence of viral respiratory
infection, and the degree of HLA histocompatibility. In the
presence of an HLA-identical family donor (20–30% of SCID
patients), HSCT can be performed in certain SCID forms
(particularly those with an absence of NK cells) without any
conditioning regimen, and its course is characterized by the
remarkable rarity of acute and chronic GVHD without any
prophylaxis, and by the rapid development of T lymphocyte
function after transplant. The restoration of B lymphocyte function
nearly always occurs in patients with the B lymphocyte +ve form
of SCID, but is absent in 40% of those with a B lymphocyte − ve
form. In the absence of an HLA-identical family donor, HSCT from
a partially HLA-compatible donor is recommended. In this respect,
the use of a conditioning regimen has a positive effect on survival
in the B lymphocyte—SCID group but not in other SCID groups.
HSCT from unrelated HLA-compatible donors and unrelated
umbilical CB and haploidentical HSCT from related donors (that
is, one of the two parents) are alternative options, with improving
outcomes.228
Other primary immunodeficiencies. Allo-HSCT can cure most of
the T lymphocyte immunodeficiencies, Wiskott-Aldrich syndrome,
phagocyte disorders such as leukocyte adhesion deficiency and
chronic granulomatous diseases, haemophagocytic syndromes
such as familial lymphohistiocytosis, and a growing number of
other immunodeficiencies. These patients require conditioning.
As for patients with SCID, prognostic factors include age at
transplant, the type of primary immunodeficiency, and the clinical
state at the time of diagnosis, in particular, the presence of viral
respiratory infection, and the degree of HLA histocompatibility.
Survival is similar using an HLA-identical family donor or HLA-
matched unrelated donor.228 Patients transplanted at an early age
have a better outcome than those transplanted when older.
Inherited diseases: metabolic diseases. Most of the metabolic
diseases considered for HSCT are lysosomal storage diseases that
rely on transfer of enzyme from donor-derived blood cells to the
reticuloendothelial system and solid organs. The successful
outcome of HSCT can be affected by the lack of engraftment
(secondary rejection is comparatively common), the enzyme levels
of the donor (lower if they are a sibling carrier of the disease), and
the degree of sustained donor chimerism and possibly by the
immune processes directed against the normal donor enzyme. CB
transplantation is particularly successful in patients with Hurler's
Syndrome.229 In diseases with the central nervous system
involvement, amelioration is dependent on the replacement of
recipient microglial cells by cells of donor origin. This process is
slow and the time taken to process abnormal storage material
produces a delay between transplant and disease stabilization.
This can last up to 15 months, making it necessary to predict the
quality of life 18 months beyond the first consideration of HSCT
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(allowing for a donor search, clinical assessment and
conditioning).
Aplastic anaemia, pure red cell aplasia (Blackfan-Diamond) and
Fanconi anaemia
An allo-HSCT with an HLA-identical family donor is the treatment
of choice for children with acquired SAA. A course of intensive
immunosuppressive therapy (ATG and CYA) is one option for
patients who lack an HLA-compatible family donor. The search for
an unrelated donor should be initiated before they receive the
immunosuppressive therapy. An alternative option for children
who lack an HLA-compatible family donor is upfront matched
unrelated donor HSCT if a donor is readily available, as results of
MUD HSCT in children are now similar to matched sibling
HSCT.230–234 For children who fail their first course of immuno-
suppression, if a well-matched unrelated donor is identified, the
transplant or a second course of immunosuppression should be
given, according to clinical status. Children with Blackfan-Diamond
anaemia having a matched sibling should be transplanted if they
do not respond to steroids.235 Children with FA should be
transplanted if they have a HLA-identical sibling donor or a well-
matched unrelated donor. For patients who lack a well-matched
donor, HSCT should be considered with a mismatched unrelated
donor or with CB stem cells in the context of a clinical protocol.
Haemoglobinopathies
The outcome of HSCT for thalassaemia has progressively improved
with the identification of the Pesaro Classes of Risk and the
development of new conditioning regimens and supportive
therapies. Allo-HSCT from a healthy related sibling donor or a
related CB represents the treatment of choice for young patients
with homozygous thalassaemia. For patients who lack a sibling
donor, a transplant from a well-matched unrelated donor is a
possibility.29 Extended haplotype matching seems to impact
positively on prognosis after unrelated donor HSCT.236–240
Developments of conventional therapy have improved both the
quality and the duration of life for patients with sickle cell disease;
however, today a prediction on the severity and onset of
complications is not possible. For this reason, HSCT from an
HLA-identical sibling or—for a small subset of patients—from a
well-matched non-sibling donor should be offered.241–244
Solid tumours
Neuroblastoma (stage 4 beyond the age of 1 year, or high-risk
factors in lower stages) is still the only indication where the benefit
of auto-HSCT has been demonstrated by randomized trials.245,246
Although to date the published results do not demonstrate an
unequivocal benefit for consolidation with HDT, children and
adolescents with solid tumours might undergo auto-HSCT follow-
ing high-dose chemotherapy within clinical research trials, pre-
ferably as part of first-line treatment strategies in the following
situations: neuroblastoma (high risk, 4CR1), Ewing’s Sarcoma (high
risk or4CR1), Brain tumours: children with medulloblastoma and
high-grade gliomas responsive to chemotherapy in an attempt to
avoid or postpone radiotherapy, soft tissue sarcoma: stage IV or in
responding relapse, germ cell tumours: after a relapse or with
progressive disease and Wilm's tumour: relapse.
Generally, allo-HSCT in children with solid tumours should only
be explored within prospective trials in highly experienced
centres.
Autoimmune diseases
For paediatric patients, auto-HSCT is a CO for carefully selected
subpopulations of patients with juvenile inflammatory arthritis
with polyarticular course or polyarticular onset, no response to
equivalent prednisone dose of 2 mg/kg/day (max 60mg daily) for
eight consecutive weeks, and inadequate response to, or
intolerance to, at least two disease modifying antirheumatic
drugs, including biological agents or unacceptable toxicity from
disease modifying antirheumatic drugs or corticosteroid therapy
(level II), for SSc, systemic lupus erythematosus, Crohn’s disease
which requires special consideration and appropriate expertise in
patient selection (level III), autoimmune cytopenia where no fully
HLA compatible sibling or unrelated donor can be identified, or in
patients with Evans’ syndrome with no 9/10 HLA matched
unrelated donor (level II).
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